Lucid Diagnostics (NASDAQ:LUCD) Announces Earnings Results

Lucid Diagnostics (NASDAQ:LUCDGet Free Report) announced its quarterly earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, Yahoo Finance reports. The business had revenue of $1.04 million for the quarter. Lucid Diagnostics had a negative net margin of 2,169.07% and a negative return on equity of 8,334.14%. During the same quarter last year, the business posted ($0.22) earnings per share.

Lucid Diagnostics Stock Down 6.6 %

LUCD opened at $0.99 on Wednesday. The firm has a market capitalization of $44.22 million, a P/E ratio of -0.78 and a beta of 1.73. The firm’s 50 day moving average is $1.30 and its 200-day moving average is $1.34. Lucid Diagnostics has a 52-week low of $0.97 and a 52-week high of $1.85.

Institutional Trading of Lucid Diagnostics

Hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. bought a new stake in shares of Lucid Diagnostics in the first quarter worth $209,000. Geode Capital Management LLC increased its stake in shares of Lucid Diagnostics by 245.3% in the second quarter. Geode Capital Management LLC now owns 143,465 shares of the company’s stock worth $199,000 after buying an additional 101,922 shares during the last quarter. State Street Corp increased its stake in shares of Lucid Diagnostics by 24.4% in the first quarter. State Street Corp now owns 56,693 shares of the company’s stock worth $190,000 after buying an additional 11,121 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of Lucid Diagnostics in the first quarter worth $122,000. Finally, Citadel Advisors LLC bought a new stake in shares of Lucid Diagnostics in the second quarter worth $87,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.

Featured Articles

Earnings History for Lucid Diagnostics (NASDAQ:LUCD)

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.